Financial Performance - Payoneer reported record quarterly revenue of $270.9 million for Q3 2025, a 9% increase year-over-year[2] - Revenue excluding interest income grew 15% year-over-year, driven by 9% volume growth and significant take rate expansion with SMB customers[7] - SMB customer revenue reached $192 million, reflecting a 17% year-over-year growth, with B2B SMBs revenue up 27% to $62 million[7] - The company raised its 2025 revenue guidance to a range of $1,050 million to $1,070 million, with adjusted EBITDA guidance of $270 million to $275 million[9] - Total revenues for the three months ended September 30, 2025, were $270,850,000, representing a 9.5% increase from $248,274,000 in the same period of 2024[20] - Adjusted EBITDA for the three months ended September 30, 2025, was $71,267,000, compared to $69,268,000 in 2024, reflecting a 2.9% increase[25] - Net income for Q3 2025 was $14.1 million, a decrease of 66% compared to the previous year[2] - Net income for the three months ended September 30, 2025, was $14,123,000, down from $41,574,000 in 2024, a decrease of 66.1%[25] - Net income for the nine months ended September 30, 2025, was $54,180, a decrease of 47% compared to $102,973 in 2024[32] Customer Metrics - Active Ideal Customer Profiles (ICPs) decreased by 2% year-over-year to 548,000[2] - The average revenue per user (ARPU) excluding interest income grew 22% year-over-year, marking the fifth consecutive quarter of over 20% growth[7] - Customer funds on the platform grew by 17% year-over-year to $7.1 billion as of September 30, 2025[12] - Customer funds increased to $6,772,912,000 as of September 30, 2025, compared to $6,439,153,000 at the end of 2024, a rise of 5.2%[30] Regional Performance - Greater China revenue for the three months ended September 30, 2025, was $91,159,000, up from $85,111,000 in 2024, an increase of 3.7%[22] - North America revenue increased to $26,302,000 in 2025 from $25,162,000 in 2024, a growth of 4.5%[22] Cash Flow and Investments - Net cash provided by operating activities rose to $178,577, up 36% from $131,039 in the previous year[32] - Net cash used in investing activities was $(169,379), significantly improved from $(1,814,106) in 2024[32] - Cash, cash equivalents, restricted cash, and customer funds at the end of the period totaled $5,709,604, an increase from $4,898,477 in 2024[32] - Capital advances extended to customers decreased to $(235,407) from $(260,435), a reduction of 10%[32] - Purchases of investments in available-for-sale debt securities were $(351,824), a decrease of 72% compared to $(1,255,686) in 2024[32] Shareholder Metrics - The weighted average common shares outstanding increased to 368,266,611 in 2025 from 357,297,824 in 2024, a rise of 3.0%[28] - The company reported a diluted earnings per share of $0.04 for the three months ended September 30, 2025, down from $0.11 in 2024, a decrease of 63.6%[28] - Common stock repurchased amounted to $(95,029), down from $(120,457) in the previous year, indicating a 21% reduction[32] Depreciation and Amortization - Depreciation and amortization increased to $46,083 from $33,630, reflecting a 37% rise year-over-year[32] Transaction Costs - The transaction costs as a percentage of revenue were approximately 16.0%[9] Other Financial Metrics - Payoneer experienced a 19% year-over-year increase in spend on Payoneer cards, totaling $1.6 billion[12] - The effect of exchange rate changes on cash and cash equivalents resulted in a gain of $5,177, compared to a gain of $109 in the previous year[32]

Revenue Performance - Third quarter revenue was $260.1 million, an increase of $9.5 million or 4% compared to the third quarter of 2024[4] - Revenue from the Content product offering decreased by $9.3 million, or 5%, to $194.4 million, representing 75% of total revenue[5] - Revenue from Data, Distribution, and Services increased by $18.8 million, or 40%, to $65.7 million, accounting for 25% of total revenue[6] - Revenue for Q3 2025 was $260,094,000, a 3.0% increase from $250,588,000 in Q3 2024[36] - Total revenue for Q3 2025 was $260,094 million, representing a growth of 4% from $250,588 million in Q3 2024[47] Net Income and Earnings - Net income for the third quarter was $13.4 million, down from $17.6 million, with net income per diluted share at $0.37 compared to $0.50[7][8] - Net income for Q3 2025 was $13,387,000, down 24.8% from $17,615,000 in Q3 2024[36] - Basic earnings per share for Q3 2025 was $0.38, compared to $0.50 in Q3 2024, reflecting a decline of 24.0%[36] - Adjusted net income for Q3 2025 was $36,429 million, compared to $46,351 million in Q3 2024, reflecting a decline of 21.4%[43] Cash Flow and Liquidity - Cash and cash equivalents increased by $49.1 million to $165.5 million, driven by $78.4 million of net cash from operating activities[12] - Cash and cash equivalents increased to $165,536,000 as of September 30, 2025, up from $111,251,000 at the end of 2024[38] - Net cash provided by operating activities for the nine months ended September 30, 2025, was $130,473,000, compared to $24,680,000 for the same period in 2024[40] - Net cash provided by operating activities for Q3 2025 was $78,390 million, a significant increase from a cash outflow of $11,585 million in Q3 2024[48] - Adjusted free cash flow was $75.2 million, an increase of $29.6 million from the third quarter of 2024[15] - Adjusted free cash flow for Q3 2025 was $75,224 million, compared to $45,672 million in Q3 2024, marking a growth of 64.7%[48] Subscriber Metrics - The company reported 1,060,000 subscribers at the end of the period, with average revenue per customer increasing to $279[16] - The number of subscribers at the end of Q3 2025 was 1,060,000, a decrease from 1,105,000 in Q3 2024[51] - Average revenue per customer for the last twelve months was $279 in Q3 2025, up from $254 in Q3 2024[51] Operating Expenses and Profitability - Operating expenses decreased to $227,603,000 in Q3 2025 from $232,439,000 in Q3 2024, a reduction of 2.5%[36] - Adjusted EBITDA was $79.4 million, an increase of $9.4 million or 13%, with an adjusted EBITDA margin of 30.5%[11] - Adjusted EBITDA for Q3 2025 was $79,429 million, up from $69,997 million in Q3 2024, indicating a growth of 13.0%[47] - The adjusted EBITDA margin improved to 30.5% in Q3 2025 from 27.9% in Q3 2024[47] Assets and Liabilities - Total assets rose to $1,375,599,000 as of September 30, 2025, compared to $1,309,156,000 at the end of 2024, an increase of 5.1%[38] - Total liabilities decreased slightly to $781,238,000 as of September 30, 2025, from $790,806,000 at the end of 2024[38] - The company reported a decrease in deferred revenue to $211,565,000 as of September 30, 2025, from $225,489,000 at the end of 2024[38] Strategic Developments - The pending merger with Getty Images is ongoing, with the company committed to securing necessary clearances[3][29] - The company will not provide financial guidance due to the pending merger transaction[30] - The company plans to continue focusing on new product development and market expansion strategies[33] Compensation and Depreciation - Total non-cash equity-based compensation for Q3 2025 was $12,962,000, a decrease of 17% from $15,625,000 in Q2 2025[55] - Cost of revenue depreciation for Q3 2025 was $21,028,000, an increase of 1% from $20,804,000 in Q2 2025[56] - General and administrative expenses for equity-based compensation in Q3 2025 were $6,966,000, down 23% from $9,005,000 in Q2 2025[55] - Total depreciation and amortization for Q3 2025 was $22,877,000, an increase of 1% from $22,611,000 in Q2 2025[56] - Product development equity-based compensation for Q3 2025 was $3,370,000, a decrease of 5% from $3,529,000 in Q2 2025[55] - Sales and marketing equity-based compensation for Q3 2025 was $2,098,000, a decrease of 18% from $2,559,000 in Q2 2025[55] - Cost of revenue for equity-based compensation in Q3 2025 was $528,000, a slight decrease from $532,000 in Q2 2025[55] - General and administrative depreciation for Q3 2025 was $1,849,000, an increase of 2% from $1,807,000 in Q2 2025[56] - Total equity-based compensation in Q2 2025 was $15,625,000, compared to $17,884,000 in Q1 2025, indicating a downward trend[55] - Total depreciation and amortization in Q4 2024 was $23,287,000, which is higher than the $22,877,000 reported in Q3 2025[56]

Revenue Performance - Net revenue for Q3 2025 reached a record $778.2 million, an increase of 2.3% from $760.6 million in Q3 2024[7] - Net revenue for Q3 2025 was $778.2 million, a 2.1% increase from $760.6 million in Q3 2024[22] - Total consolidated net revenue for Q3 2025 reached $778.2 million, compared to $760.6 million in Q3 2024, marking a growth of 2.1%[30] Income and Profitability - Net income increased 8.5% to a record $74.4 million, with net income per diluted share rising 12.3% to $2.74[7][14] - Net income for Q3 2025 was $74.4 million, up from $68.6 million in Q3 2024, resulting in a diluted earnings per share of $2.74[22] - Adjusted net income for Q3 2025 was $86.4 million, compared to $80.1 million in Q3 2024, indicating an increase of 4.1%[40] - Operating income for Q3 2025 was $106.8 million, an increase from $101.3 million in Q3 2024, reflecting a growth of 5.4%[30] - Adjusted EBITDA increased 5.7% to a record $139.9 million, representing an adjusted EBITDA margin of 18.0%[16] - Adjusted EBITDA for the three months ended September 30, 2025, was $139.9 million, compared to $132.3 million in the same period of 2024, reflecting a margin of 18.0%[49] Revenue Segmentation - Installation revenue increased by 1.0% to $721.1 million, while other revenue rose 21.7% to $57.1 million[7] - Installation segment revenue for Q3 2025 was $721.1 million, a slight increase from $713.7 million in Q3 2024, representing a growth of 1.9%[30] - Residential new construction accounted for 70% of the Installation segment revenue in Q3 2025, totaling $540.3 million, slightly down from 72% in Q3 2024[32] Cash Flow and Dividends - Net cash flow from operations increased 22.4% to $124.1 million, with cash and cash equivalents totaling $333.3 million as of September 30, 2025[7] - Cash and cash equivalents increased to $333.3 million as of September 30, 2025, from $327.6 million at the end of 2024[24] - The company declared cash dividends of $0.37 per share in Q3 2025, up from $0.35 per share in Q3 2024[22] - A quarterly cash dividend of $0.37 per share was declared, representing a 6% increase from the previous year[8] Expenses and Liabilities - The company’s operating expenses for Q3 2025 were $157.4 million, compared to $155.5 million in Q3 2024, showing a slight increase of 1.2%[30] - Total liabilities increased to $1,372.5 million as of September 30, 2025, from $1,354.6 million at the end of 2024[24] Sales Growth - Residential same branch sales decreased by 2.8%, while commercial same branch sales increased by 11.7%[10] - The company reported a commercial sales growth of 12.2% for the three months ended September 30, 2025, compared to 7.7% in the same period of 2024[51] - Same branch sales growth for the three months ended September 30, 2025, was 0.4%, a decrease from 5.2% in the same period of 2024[51] - The company experienced a decline in residential sales growth of (1.5)% for the three months ended September 30, 2025, compared to a growth of 7.7% in the same period of 2024[51] Asset Management - Total assets decreased to $2,051.1 million as of September 30, 2025, compared to $2,059.9 million at December 31, 2024[24] - Cash flows from operating activities for the nine months ended September 30, 2025, were $306.5 million, compared to $265.2 million in 2024[26] Share Repurchase - The company repurchased 200,000 shares of common stock at a total cost of $51.5 million during Q3 2025[9] - The company repurchased $134.9 million of common stock during the nine months ended September 30, 2025[28]

Financial Position - As of September 30, 2025, the company had cash, cash equivalents, and investments totaling $349.0 million, expected to fund operations into mid-2027[120] - As of September 30, 2025, the company had cash, cash equivalents, and investments totaling $349.0 million, with $50.8 million in cash and cash equivalents, $195.4 million in short-term investments, and $102.8 million in long-term investments[146] - The company raised $8.1 million from financing activities during the nine months ended September 30, 2025, mainly from the ATM program and employee stock option exercises[157] - The company has access to up to $200.0 million in term loans, with $110.0 million already received and additional tranches available upon achieving specific milestones[147][149] - The term loans are set to mature on December 1, 2029, with an option to extend to December 1, 2030, depending on certain conditions[150] Research and Development - The company is developing ORX750, an OX2R agonist, currently in Phase 2a clinical trials, with 55 participants completing dosing as of September 23, 2025[109] - ORX750 demonstrated statistically significant improvements in mean sleep latency on the Maintenance of Wakefulness Test (MWT) with a p-value of 0.0213 compared to placebo[111] - ORX142, another OX2R agonist, is in Phase 1 clinical trials, with 89 healthy adult participants dosed as of October 3, 2025, showing rapid onset of action and well-tolerated at all doses[117] - The Phase 2a study of ORX750 is expected to enable dose selection for a registrational program planned for the first quarter of 2026[112] - The company is advancing ORX489, its most potent OX2R agonist, into IND-enabling studies with clinical studies planned for the first quarter of 2026[118] - Research and development expenses are expected to increase significantly due to costs associated with clinical trials and regulatory filings for current and future product candidates[122] Financial Performance - The company recorded a net loss of $54.9 million for the three months ended September 30, 2025, compared to a net loss of $42.6 million for the same period in 2024, reflecting a 28.8% increase in losses[133] - For the nine months ended September 30, 2025, research and development expenses totaled $117.7 million, up 31.7% from $89.4 million for the same period in 2024[141] - Research and development expenses for the three months ended September 30, 2025, were $41.6 million, an increase of 22.5% from $33.9 million for the same period in 2024[134] - The OX2R agonist program accounted for $35.6 million in research and development expenses for the three months ended September 30, 2025, compared to $11.7 million in the same period of 2024[134] - The company recognized $15.0 million in license and other revenue during the nine months ended September 30, 2025, related to an upfront payment from Genmab A/S[140] - Interest and investment income for the nine months ended September 30, 2025, was $16.0 million, an increase of 75.2% from $9.2 million for the same period in 2024[143] - General and administrative expenses for the nine months ended September 30, 2025, were $36.5 million, a slight decrease from $37.1 million for the same period in 2024[142] - Interest expense for the nine months ended September 30, 2025, was $8.7 million, up 13.1% from $7.6 million for the same period in 2024[144] - Other non-operating income for the nine months ended September 30, 2025, was $2.8 million, compared to $2.3 million for the same period in 2024, primarily due to foreign currency transaction gains[145] Operational Challenges - The company has incurred recurring losses and negative cash flows since inception, primarily funded through equity securities and debt financing[120] - The company expects to continue incurring significant development costs as it progresses through clinical trials and regulatory approvals[127] - During the nine months ended September 30, 2025, the company used $138.0 million in operating activities, reflecting a net loss of $131.4 million, adjusted by non-cash charges of $22.3 million[154] - The company incurred net cash used in investing activities of $200.4 million during the nine months ended September 30, 2025, primarily due to investments in marketable securities[156] - The company anticipates significant increases in expenses as it continues the development of product candidates and seeks marketing approvals, necessitating substantial additional funding[158] Licensing and Partnerships - The company has out-licensed its LockBody technology platform to Genmab for up to three targets, indicating potential revenue generation opportunities[121] Company Classification - The company is classified as an emerging growth company and a smaller reporting company, allowing it to benefit from reduced reporting requirements[164][166]

Exhibit 99.1 JLL Reports Financial Results for Third-Quarter 2025 JLL achieved sixth consecutive quarter of double-digit revenue growth and delivered a 45% increase in diluted earnings per share CHICAGO, November 5, 2025 – Jones Lang LaSalle Incorporated (NYSE: JLL) today reported operating performance for the third quarter of 2025 with diluted earnings per share of $4.61 (up 45%) and adjusted diluted earnings per share of $4.50 (up 29%). Transactional revenues returned to double-digit growth this quarter a ...

Financial Performance - Royalty Pharma reported Portfolio Receipts of $814 million for Q3 2025, an 11% increase from $735 million in Q3 2024[5]. - Royalty Receipts grew 11% to $811 million in Q3 2025, driven by Voranigo, Tremfya, and the cystic fibrosis franchise[7]. - Adjusted EBITDA for Q3 2025 was $779 million, a 15% increase from $679 million in Q3 2024[5]. - The company reported total income and other revenues of $609 million for Q3 2025, compared to $565 million in Q3 2024, marking an increase of 7.8%[48]. - Consolidated net income attributable to Royalty Pharma plc for Q3 2025 was $288 million, down from $544 million in Q3 2024, representing a decline of 47%[48]. - Portfolio Cash Flow for Q3 2025 was $657 million, up 6% from $617 million in Q3 2024[5]. - Adjusted EBITDA for the quarter was reported at $779 million, an increase from $679 million in the previous year, indicating a strong operational performance[57]. - Net cash provided by operating activities was $703 million for the quarter, slightly down from $704 million year-over-year, with a total of $1.663 billion for the year compared to $2.026 billion last year[54]. Guidance and Projections - The company raised its full year 2025 guidance for Portfolio Receipts to between $3,200 million and $3,250 million, reflecting expected growth of 14% to 16%[4]. - Royalty Pharma's 2025 Portfolio Receipts guidance is projected to be between $3,200 million and $3,250 million, reflecting a year-over-year growth of approximately 14% to 16%[25]. - Operating and professional costs are expected to be around 9% to 9.5% of Portfolio Receipts, with one-time payments of approximately $70 million anticipated in 2025[26]. - Total interest paid in 2025 is expected to be approximately $275 million, with projections for 2026 indicating an increase to around $350 million to $360 million[27]. - The company expects a negligible foreign exchange impact on Portfolio Receipts, assuming current rates remain stable throughout 2025[25]. Capital Management - Capital Deployment in Q3 2025 was $1.0 billion, primarily for new royalty acquisitions and research funding[16]. - Royalty Pharma repurchased approximately 4 million Class A ordinary shares for $152 million in Q3 2025, totaling $1.2 billion in share repurchases for the first nine months of 2025[12]. - The company reported a net cash used in investing activities of $958 million for the quarter, compared to $1.193 billion in the previous year, with significant acquisitions of financial royalty assets totaling $962 million[54]. - Net cash provided by financing activities was $563 million for the quarter, a turnaround from a net cash used of $326 million in the previous year, primarily due to proceeds from long-term debt issuance[54]. - The company reported a total of $1,275 million in proceeds from a revolving credit facility, which was fully repaid in the same period, indicating active management of liquidity[54]. Assets and Liabilities - The company had cash and cash equivalents of $939 million and total debt of $9.2 billion as of September 30, 2025[11]. - Total current and non-current financial royalty assets increased to $16,624 million in Q3 2025 from $15,911 million in Q3 2024, reflecting a growth of 4.5%[51]. - Royalty Pharma's total liabilities increased to $9,726 million in Q3 2025 from $7,880 million in Q3 2024, indicating a rise of 23.3%[51]. - Royalty Pharma's cash and cash equivalents stood at $939 million as of September 30, 2025, slightly up from $929 million a year earlier[51]. - The company ended the period with cash and cash equivalents of $939 million, compared to $950 million at the end of the previous quarter[54]. Strategic Initiatives - The company expects to initiate a Phase 3 trial for daraxonrasib in metastatic pancreatic cancer in Q4 2025, supported by positive initial data[7]. - Royalty Pharma acquired a royalty on Amgen's Imdelltra for up to $950 million and entered into a funding agreement on obexelimab for up to $300 million[7]. - The company made milestone payments totaling $269 million during the year, indicating ongoing investment in development-stage projects[54]. - The company announced the release of Deloitte's report on the biopharma royalty market, highlighting the critical role of royalties in funding biopharma innovation[29]. Cash Flow and Collections - Cash collections from financial royalty assets increased to $882 million in the latest quarter, up from $792 million year-over-year, while total cash collections for the year reached $2.439 billion, compared to $2.206 billion last year[54]. - Portfolio Cash Flow, defined as Adjusted EBITDA minus net interest paid, was $657 million for the quarter, up from $617 million year-over-year, reflecting improved cash generation capabilities[57]. - Distributions to legacy non-controlling interests were $102 million for the quarter, consistent with the previous year, highlighting stable cash outflows to stakeholders[57].

Financial Performance - The company reported a net loss of $14.3 million for the three months ended September 30, 2025, compared to a net loss of $10.5 million for the same period in 2024, representing an increase of 36%[66]. - The company has incurred significant operating losses since inception, with an accumulated deficit of $415.5 million as of September 30, 2025[56]. - Total operating expenses for the nine months ended September 30, 2025, were $54.8 million, an increase of $13.9 million, or 34%, compared to $40.9 million for the same period in 2024[70]. - For the nine months ended September 30, 2025, the company used $35.9 million in operating activities, compared to $35.7 million in the same period of 2024[78][79]. Research and Development - Research and development expenses increased by $4.2 million, or 49%, for the three months ended September 30, 2025, totaling $12.8 million, driven by costs related to the new pipeline candidate CTX-10726[67]. - Research and development expenses for the nine months ended September 30, 2025, increased by $13 million, or 44%, totaling $42.3 million, with significant increases in manufacturing expenses related to tovecimig and CTX-10726[72]. - The company plans to present full topline data from the Phase 1 study of CTX-8371 at a medical meeting in the first half of 2026[54]. Cash and Funding - The company had cash, cash equivalents, and marketable securities of $220 million as of September 30, 2025, which is expected to fund operations into 2028[57]. - Cash used in investing activities for the nine months ended September 30, 2025, was $90.0 million, while cash provided by investing activities in 2024 was $31.4 million[80]. - Financing activities provided $128.5 million in cash during the nine months ended September 30, 2025, a significant increase from $17.4 million in 2024[81]. - The company expects to fund its operating expenses and capital expenditures into 2028 based on current cash and marketable securities[82]. - Additional funding will be required for the clinical development of product candidates, including tovecimig, CTX-471, CTX-8371, and CTX-10726[82]. - Future funding may involve equity and debt financings, collaborations, and strategic alliances, which could dilute ownership interests[84]. - The company may need to delay or reduce product development if additional funds are not raised when needed[84]. Revenue and Expenses - The company reported no licensing revenue for the nine months ended September 30, 2025, compared to $850 thousand for the same period in 2024[71]. - General and administrative expenses decreased by $0.6 million, or 18%, for the three months ended September 30, 2025, totaling $2.99 million[68]. - Interest income decreased by $0.2 million, or 11%, for the three months ended September 30, 2025, due to a lower average balance of cash and marketable securities[69].

Financial Performance - Total revenue for Q3 2025 was $1.752 million, compared to $1.136 million in Q3 2024, representing a 54.3% increase year-over-year[19] - Total operating expenses for Q3 2025 were $19.377 million, up from $14.388 million in Q3 2024, reflecting a 34.7% increase[19] - The net loss for Q3 2025 was $20.051 million, compared to a net loss of $12.970 million in Q3 2024, indicating a 55.2% increase in losses year-over-year[19] - Research and development expenses for Q3 2025 were $11.149 million, compared to $8.108 million in Q3 2024, marking a 37.5% increase[19] Cash Position - Cash, cash equivalents, and restricted cash totaled $32.9 million as of September 30, 2025, down from $58.8 million as of December 31, 2024[11] - The company closed a $20 million registered direct offering in Q3 2025, which is expected to extend the cash runway into Q2 2026[6] Clinical Trials and Development - Enrollment in the OCU400 Phase 3 liMeLiGhT clinical trial is nearing completion, with 50% enrollment achieved to date[5] - The OCU410ST Phase 2/3 GARDian3 trial is ahead of schedule, with interim data expected mid-year 2026[5] - The company intends to file three Biologics License Applications (BLAs) in the next three years, with the first expected in 1H 2026[2] Partnerships and Sales Projections - The company has an exclusive licensing agreement with Kwangdong Pharmaceutical for OCU400 in South Korea, projected to generate $180 million in sales over the first 10 years[2]

Financial Performance - The net loss for Q3 2025 was $14.3 million, or $0.08 per share, compared to a net loss of $10.5 million, or $0.08 per share, for the same period in 2024[8] - The company reported a total operating loss of $15.8 million for Q3 2025, compared to $12.2 million for Q3 2024[17] - Total liabilities as of September 30, 2025, were $21.6 million, while total stockholders' equity was $209.6 million[20] Research and Development - Research and Development (R&D) expenses increased by 49% to $12.8 million in Q3 2025, up from $8.6 million in Q3 2024, primarily due to manufacturing and IND-enabling costs for CTX-10726[9] - CTX-10726 is on track for IND filing in Q4 2025, with initial Phase 1 clinical data expected in H2 2026[5] - The company plans to initiate a Phase 2 trial of CTX-471 in Q1 2026 for tumors expressing NCAM (CD56)[10] Cash Position - Cash and marketable securities as of September 30, 2025, were $220 million, up from $127 million as of December 31, 2024, providing a cash runway into 2028[12] - The financing round in August raised $138 million, supporting ongoing clinical development and expansion plans[3] Clinical Trials and Studies - The company expects to report overall survival (OS) and progression-free survival (PFS) data for tovecimig in late Q1 2026, based on a continuing trend of decreased mortality in the ongoing COMPANION-002 study[4] - Cohort expansions for CTX-8371 in patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) are expected to begin in Q4 2025[5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-39497 UNITY SOFTWARE INC. (Exact name of registrant as specified in its charter) Delaware 27-0334803 (State ...